Vista Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vista Therapeutics's estimated annual revenue is currently $505k per year.
- Vista Therapeutics's estimated revenue per employee is $101,000
Employee Data
- Vista Therapeutics has 5 Employees.
- Vista Therapeutics grew their employee count by 0% last year.
Vista Therapeutics's People
Name | Title | Email/Phone |
---|
Vista Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 14 | -7% | N/A | N/A |
#2 | $0.2M | 2 | -60% | N/A | N/A |
#3 | $3.8M | 27 | -4% | N/A | N/A |
#4 | $0.6M | 6 | -14% | N/A | N/A |
#5 | $1.3M | 11 | 22% | N/A | N/A |
#6 | $3M | 21 | -25% | N/A | N/A |
#7 | $1.5M | 12 | -14% | N/A | N/A |
#8 | $0.5M | 5 | 0% | N/A | N/A |
#9 | $50.8M | 23 | -12% | $2M | N/A |
#10 | $12.4M | 68 | -4% | N/A | N/A |
What Is Vista Therapeutics?
Vista Therapeutics has been developing, collaborating, and fine tuning the NanoBioSensorTM Platform based on research developed in the Charles M. Lieber Laboratory at Harvard University. The software, instrument, and functionalized NanoCards for target immobilization are based on silicon nanowires that act as Field Effect Transistors (FETs) to quantitatively measure and provide kinetic analysis of real time changes in conductance with high sensitivity based on detector:target sample interactions without requiring secondary detection molecules. Applications include: -Multiplex biomarker measurement in body fluids and cell culture matrices -Bioprocess monitoring -Toxicology/Pharmacokinetics -Portable option for field based diagnostics -Pathogen detection -Environmental monitoring -Historical exposure/vaccine analyis (IgM or IgG formation) -PCR/rtPCR coming soon...
keywords:N/AN/A
Total Funding
5
Number of Employees
$505k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 5 | -17% | N/A |
#2 | $0.8M | 5 | -84% | N/A |
#3 | $0.4M | 5 | -84% | N/A |
#4 | $0.4M | 6 | 20% | N/A |
#5 | $0.8M | 6 | -40% | N/A |